An intelligence report has been added to the portfolio of WiseGuyReports titled, “Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022”.
The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Migraine Pipeline Drugs Market by assessing the potential of the seven drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the seven drugs, the product profile, description and regulatory phase of each of the seven drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the seven drugs to present the current perspective.
The report titled “Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022” also analyzes the overall sizing, growth and forecast of Migraine Drugs Market By Type (Acute and Prophylaxis) for the global market as well as for countries including United States, United Kingdom, Japan, France, Italy and Germany.
Over the recent years, the Migraine Drugs market is growing rapidly due to rising prevalence of migraine patients around the world. Globally, the growth of Migraine Drugs market is driven by rising awareness regarding migraine and available treatments
The global migraine drugs market is projected to display a robust growth represented by a CAGR of 14.48% during 2017– 2022, chiefly driven by rising consumption of unhealthy food coupled with unmet need By the present drugs for the treatment of migraine. The report has covered and analysed the present migraine drugs in the market and has also analysed potential of seven major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global migraine pipeline drugs market.
Scope of the Report
Migraine Pipeline Drugs Assessment – Drug X1, X2, X3, X4, X5, X6, X7 (Forecast Period: 2019-2022)
– Market Potential
– Clinical Trials
– Product Description
– Regulatory Phases
– 7Ps Analysis
Global Migraine Drugs Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
– Market Sizing and Growth
– Market Sizing and Growth By Type – Acute and Prophylaxis
Country Analysis US, UK, Japan, France, Italy, Germany (Actual Period: 2012-2016, Forecast Period: 2017-2022)
– Market Sizing and Growth
Other Report Highlights
– Market Dynamics – Drivers, Challenges
– Company Analysis – Amgen Biopharmaceuticals, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline
Table of Contents
- Research Methodology
- Executive Summary
- Migraine – An Overview
- Treatment of Migraine
- Anti-Migraine Pipeline Drugs Analysis
- Global Migraine Drugs Market: Growth and Forecast
- Global Migraine Drugs Market – Analysis By Type
- Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW)
- Market Dynamics
- Company Profiles
10.3. Eli Lilly
10.4. Alder Pharmaceuticals
10.5. Teva Pharmaceuticals
10.8. Impax Laboratories
10.9. Glaxo Smithkline
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)